▼ -30.25% Downside Potential
This price target is based on 10 analysts offering 12 month price targets for Glaukos in the last 3 months. The average price target is $58.40, with a high forecast of $80.00 and a low forecast of $36.00. The average price target represents a -30.25% upside from the last price of $83.73.
The current consensus among 10 polled investment analysts is to hold stock in Glaukos. This Hold consensus rating has held steady for over two years.
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite for use as a standalone procedure in patients with refractory glaucoma; iStent SA, a two-stent product that is designed for use as a standalone glaucoma procedure; iDose Travoprost, a targeted injectable implant based on its micro-scale device-platform that is designed to deliver therapeutic levels of medication; and MicroShunt, an ab-externo device for treatment of open-angle glaucoma. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was founded in 1998 and is headquartered in San Clemente, California.